Search - tctmd.com

Displaying 201 - 220 of 334

Sort: Relevancy | Date

Presentation TCT 2014

Update: The Absorb FIRST Real-World Registry

Presenter: Mitchell W. Krucoff, John A. Ormiston, Robert-Jan van Geuns, Christoph K. Naber

September 16, 2014

Presentation TCT 2014

Update: The Absorb EXPAND Real-World Registry

Presenter: Mitchell W. Krucoff, John A. Ormiston, Robert-Jan van Geuns

September 16, 2014

Presentation TCT 2014

Featured Lecture: ABSORB II: What Has the Randomized Trial Taught us Beyond the Registries?

Presenter: Mitchell W. Krucoff, John A. Ormiston, Robert-Jan van Geuns, Patrick W. Serruys

September 16, 2014

Presentation TCT 2014

Diabetic patients treated with Bioresorbable Vascular Scaffolds show good clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB and SPIRIT trials

Presenter: Javaid Iqbal

September 16, 2014

Presentation TCT 2014

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Presenter: Bernard Chevalier

September 16, 2014

Presentation TCT 2014

Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials_

Presenter: John Ormiston

September 16, 2014

Presentation TCT 2014

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

Presenter: Bernard De Bruyne

September 16, 2014

News Industry News

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

September 16, 2014

Presentation TCT 2014

TCT 614: Detailed Morphologic Characterization of the Strut Composition Following Absorb Scaffold Placement in a Porcine Coronary Artery Model Through 48 Months

Presenter: David P. Faxon, Fumiyuki Otsuka, MD

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

Presentation TCT 2014

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

Presenter: Valentin Fuster, Patrick W. Serruys, Gregg W. Stone

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Industry News

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

September 14, 2014

News Conference News TCT 2014

ABSORB EXTEND: BVS Safe Out to 3 Years

September 14, 2014

Presentation TCT 2014

TCT 615: ABSORB EXTEND: An Interim Report on the 36-Month Clinical Outcomes from the First 250 Patients Enrolled

Presenter: Valentin Fuster, Pieter C. Smits

September 13, 2014

Presentation BRS 2014

BRS Capping of Vulnerable Plaque: PROSPECT ABSORB

Presenter: Gregg W. Stone

July 26, 2014

Presentation BRS 2014

Outcomes in Long Lesions and BRS Overlap (with Focus on Sidebranch Closure): ABSORB Extend

Presenter: Alexandre Abizaid

July 26, 2014

Presentation BRS 2014

Is ABSORB ready for an ‘all-comers’ randomized trial? The upcoming COMPARE-ABSORB trial

Presenter: P.C. Smits

July 26, 2014

Presentation BRS 2014

Outcomes of Clinical Registries with ABSORB BVS:Simple Lesions vs_ Real-World

Presenter: Roberto Diletti

July 25, 2014

Advertisement

Update: The Absorb FIRST Real-World Registry

Update: The Absorb EXPAND Real-World Registry

Featured Lecture: ABSORB II: What Has the Randomized Trial Taught us Beyond the Registries?

Diabetic patients treated with Bioresorbable Vascular Scaffolds show good clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB and SPIRIT trials

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials_

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

TCT 614: Detailed Morphologic Characterization of the Strut Composition Following Absorb Scaffold Placement in a Porcine Coronary Artery Model Through 48 Months

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

ABSORB EXTEND: BVS Safe Out to 3 Years

TCT 615: ABSORB EXTEND: An Interim Report on the 36-Month Clinical Outcomes from the First 250 Patients Enrolled

BRS Capping of Vulnerable Plaque: PROSPECT ABSORB

Outcomes in Long Lesions and BRS Overlap (with Focus on Sidebranch Closure): ABSORB Extend

Is ABSORB ready for an ‘all-comers’ randomized trial? The upcoming COMPARE-ABSORB trial

Outcomes of Clinical Registries with ABSORB BVS:Simple Lesions vs_ Real-World

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content